MEDVi: Affordable, Doctor-Led GLP-1 Weight Loss, Delivered Discreetly to Your Door

MEDVi is the LegitScript-certified telehealth platform trusted by thousands of Americans for affordable, medically supervised GLP-1 weight loss, combining compounded semaglutide and tirzepatide, board-certified clinician oversight, and all-inclusive monthly pricing starting from $179.

I had spent years trying every diet, every gym, every supplement — and the scale would not move. My MEDVi clinician was kind, walked me through what to expect, and adjusted my dose when I asked. Five months in, I am down 32 pounds, my cravings are gone, and I actually feel hopeful about my health for the first time in a decade.

— Emma R.,

Home › GLP-1 Reviews › MEDVi

MEDVi Review: Is the $179 GLP-1 Program Worth It in 2026?

MEDVi offers compounded semaglutide and tirzepatide through licensed telehealth providers at some of the lowest cash-pay prices in the category. We dug into the pricing, the certifications, and the complaints. Here's the honest breakdown.

By The HealthCompare Editorial Team • Updated May 21, 2026 • 10 min read

MEDVi

Cash-pay GLP-1 telehealth · compounded & branded options

4.0

out of 5

★★★★☆

Pricing

4.6

Access

4.5

Support

3.2

Billing clarity

3.0

$179 first month · no insurance required

Check MEDVi pricing

What we liked

Low entry price — $179 for the first month, including consultation, medication and shipping
No insurance and no long-term contract; month-to-month
LegitScript certified, with licensed providers via OpenLoop
Large, mostly positive review base (4.4–4.5 on Trustpilot)
Multiple options: compounded semaglutide, tirzepatide, and branded paths

What to watch out for

Refunds are restrictive — policy states no refund on standard cancellation
Money-back guarantee requires 5 months of adherence, minus a 25% fee
Recurring billing complaints, including charges after cancellation

Our verdict at a glance

MEDVi is a legitimate, LegitScript-certified telehealth platform that has made GLP-1 weight-loss medication far more affordable for cash-paying patients. Branded drugs like Wegovy and Ozempic often run $1,300–$1,500 a month without insurance, while MEDVi's compounded semaglutide starts at $179 for the first month. That price gap is the core of its appeal, and it's a real one.

The catch is on the back end. Across thousands of reviews, the most consistent complaints aren't about the medication or the providers — they're about billing and refunds. The money-back guarantee reportedly shifted from three months to five, standard cancellations aren't refunded, and several customers report being charged after they thought they'd cancelled. If you go in understanding those terms, MEDVi is one of the most accessible options available. If you expect easy refunds, you may be frustrated.

Bottom line: A strong pick for cash-pay patients who want low-cost GLP-1 access and who read the billing terms carefully before enrolling. Confirm current pricing and the refund policy directly on MEDVi's site before you sign up.

MEDVi pricing in 2026

MEDVi uses a flat first-month promotional price that includes your provider consultation, the medication, and shipping, then moves to standard monthly pricing. The figures below reflect the most recent publicly reported pricing as of this update — always verify on MEDVi's own site, as compounded pricing in this category shifts often.

MEDVi GLP-1 program product — MEDVi's compounded GLP-1 program. Check current pricing on the official site.

Program	First month	Ongoing / month
Compounded semaglutide (injection)	$179	$299
Compounded semaglutide (tablets)	$249	$369
Compounded tirzepatide	$279	$399
Branded Ozempic (no insurance)	—	~$1,999

There's no membership fee on the compounded path and no insurance requirement. Branded paths reportedly use a separate membership-plus-medication model.

How MEDVi works

The process is built around three steps. First, you complete an online health questionnaire covering your medical history, current medications, and weight-loss goals. Next, a licensed provider through MEDVi's clinical partner network reviews your submission — usually within about 24 hours — and makes an independent prescribing decision; MEDVi states it does not employ the physicians or influence those decisions. Finally, if approved, your medication ships directly to your door. Lab work isn't always required, though it may be requested for certain conditions.

Reputation & trust

MEDVi is a real, sizeable operation — its 2025 revenue was independently verified at around $401 million by the New York Times, and it reports having served more than 100,000 patients. It holds LegitScript certification and works with licensed U.S. providers across most states.

Customer sentiment is genuinely split by platform. On Trustpilot, MEDVi averages roughly 4.4–4.5 stars across more than 11,000 reviews; on ConsumerAffairs it sits closer to 3.6 across about 1,600 reviews. The positive reviews cite appetite suppression, real weight loss, fast shipping, and easy enrollment. The negative ones cluster heavily around billing and refunds.

Worth knowing: In 2026 the FDA issued a warning letter tied to marketing at a domain MEDVi attributes to an affiliate, and its clinical infrastructure partner reported a data breach. MEDVi's founder publicly responded committing to stop AI-generated advertising. Compounded GLP-1 medications are not FDA-approved. None of this means MEDVi is illegitimate, but these are real factors to weigh.

Who it's for

A good fit if you…

Are paying cash, want the lowest realistic entry price for GLP-1 treatment, are comfortable with compounded medication, and will read the cancellation and refund terms before enrolling.

Maybe look elsewhere if you…

Need a simple, no-questions refund policy, want only FDA-approved branded medication at a low price, or aren't comfortable with the recurring-billing complaints documented by some customers.

How we reviewed MEDVi

We reviewed MEDVi's publicly listed pricing, certifications, and program structure, and analyzed customer feedback across Trustpilot, ConsumerAffairs, and BBB, alongside reporting on its regulatory standing. Our scores are editorially independent — our affiliate relationship never changes a rating. Pricing and policy details change frequently in this category, so we note our last update date and recommend confirming specifics on MEDVi's official site.

Thinking about MEDVi?

Check current pricing, available medications, and the refund terms in your state before enrolling.

Visit MEDVi We may earn a commission. This doesn't affect our rating or the price you pay.

Why Choose MEDVi?

LegitScript-Certified Telehealth Platform

MEDVi is LegitScript certified — a third-party accreditation that verifies the platform is regularly monitored, meets healthcare transparency standards, and complies with applicable state and federal laws. This certification is a meaningful differentiator in a crowded telehealth GLP-1 market.

Board-Certified Clinician Network

Every MEDVi prescription is reviewed and issued by licensed, board-certified U.S. providers through the OpenLoop Health clinician network. MEDVi itself does not employ the prescribing physicians or influence clinical decisions — all prescribing judgment rests with the treating provider, which is exactly how telehealth is supposed to work.

All-Inclusive, Transparent Pricing

MEDVi pricing starts from $179 for the first month of compounded semaglutide injections, with no separate membership fee. Your monthly price includes the medication, physician evaluation, treatment plan, metabolic reporting, ongoing provider guidance, and free shipping. No surprise charges, no auto-escalating fees, no hidden add-ons.

Both Injection and Oral Tablet Options

Unlike most telehealth GLP-1 competitors, MEDVi offers both injectable and daily oral tablet formulations of semaglutide and tirzepatide. This flexibility matters for the substantial number of patients who cannot or will not self-inject.

What Is MEDVi?

MEDVi is a U.S.-based telehealth platform that connects adults with licensed clinicians and clinically studied GLP-1 receptor agonist medications for medically supervised weight loss. Founded in 2023 and headquartered in the United States, MEDVi specializes exclusively in GLP-1 therapy, meaning the entire platform is built around helping you access semaglutide and tirzepatide safely, affordably, and conveniently.

Unlike traditional weight-loss supplements, fat burners, or restrictive diet programs, MEDVi targets the hormonal pathways that drive hunger, satiety, and metabolic regulation. After a quick online health questionnaire, an independent licensed provider reviews your case and — if clinically appropriate, prescribes a personalized GLP-1 treatment plan that ships directly to your home.

What makes MEDVi distinct from other telehealth GLP-1 providers is the combination of low entry pricing, both injection and tablet delivery formats, LegitScript certification, and a focused single-purpose business model. MEDVi does not try to be everything for everyone, it does one thing, and it does it accessibly.

How Does MEDVi Work?

MEDVi takes a streamlined, fully online approach to medical weight loss. Most patients move from intake to first dose in just a few days. Here is how the MEDVi program works at every step.

Step 1: Online Medical Evaluation

You start with a confidential health questionnaire on the official MEDVi site, typically 5 to 10 minutes. The intake covers your medical history, current medications, weight goals, and any conditions that may affect GLP-1 eligibility. You will also upload a photo ID to verify your identity.

Step 2: Provider Review and Prescription

A licensed, board-certified provider through the OpenLoop Health network reviews your submission. MEDVi states that most reviews are completed within 24 to 48 hours. If approved, your prescribing clinician creates a personalized treatment plan, including medication selection, starting dose, and titration schedule. In some states, a brief live telehealth consultation may be required.

Step 3: Pharmacy Preparation and Cold-Pack Shipping

Once approved, your prescription is sent to a MEDVi partner compounding pharmacy, including names publicly associated with MEDVi such as Belmar Pharma Solutions. The medication is prepared, shipped with ice packs to maintain temperature integrity, and arrives at your door, typically within a few days of dispatch.

Step 4: Ongoing Telehealth Support

MEDVi includes unlimited messaging access to clinical staff, monthly check-ins, and free dose adjustments throughout your treatment. If something is not working, your provider can adjust your plan without additional consultation fees.

What Medications Are Used in MEDVi?

Every medication prescribed through MEDVi is selected based on published clinical research on the underlying active ingredients and dispensed only after independent provider review. There are no proprietary blends, no untested formulations, and no underdosed token products. Here is a closer look at the GLP-1 treatments that make MEDVi one of the most accessible medically supervised weight loss platforms in the United States.

Compounded Semaglutide Injections

Semaglutide is the active ingredient found in brand-name Ozempic and Wegovy. Compounded semaglutide through MEDVi contains the same active ingredient and is prepared by licensed U.S. compounding pharmacies operating in FDA-regulated facilities. MEDVi compounded semaglutide injections start at $179 for the first month, with refills at $299 per month — a rate MEDVi advertises as locked across dose escalation.

Compounded Tirzepatide Injections

Tirzepatide is the same active ingredient found in Mounjaro and Zepbound. As a dual GLP-1 + GIP receptor agonist, it targets two hormonal pathways simultaneously, an approach that clinical research on the branded versions suggests may produce greater average weight loss than semaglutide alone. MEDVi compounded tirzepatide injections start at $349 per month, with refills priced higher and varying by dose.

Compounded GLP-1 Oral Tablets

For patients who cannot or prefer not to self-inject, MEDVi offers daily oral tablet versions of compounded semaglutide and tirzepatide. Semaglutide tablets start at $249 for the first month; tirzepatide tablets start at $279. Note that the bioavailability data for compounded oral GLP-1 formulations is less robust than for injectable versions, discuss expected absorption and outcomes with your prescribing MEDVi provider.

Brand-Name FDA-Approved Options

For patients who prefer FDA-approved branded medications, MEDVi also offers access to Wegovy and Ozempic through partner pharmacies at standard market pricing. Note that Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved for type 2 diabetes and is sometimes prescribed off-label for weight loss based on provider judgment.

Vitamin B12 Support

Some MEDVi GLP-1 plans may include vitamin B12 to support energy metabolism and counteract potential B12 depletion that some patients experience on long-term GLP-1 therapy.

Benefits of Choosing MEDVi for Sustainable Weight Management

Clinically Supported, Steady Weight Loss

MEDVi patient-reported data shows that many users without diabetes who reach and maintain their prescribed GLP-1 dose report average losses of approximately 1 to 2 pounds per week after the first month, alongside a reduced-calorie diet and increased physical activity. Individual results vary and are not guaranteed.

True Appetite Control Without Stimulants

Unlike caffeine-based fat burners that cause jitters, crashes, and dependency, MEDVi works with your body’s own hormonal signals. No stimulants, no racing heart, no afternoon energy crashes — just consistent, predictable appetite reduction that makes a calorie deficit feel sustainable.

Improved Metabolic Health Markers

Because GLP-1 medications were originally developed to improve glycemic control, many MEDVi users report secondary benefits including more stable blood sugar, fewer sugar cravings, and improved metabolic markers alongside weight reduction. These benefits can be particularly meaningful for patients managing pre-diabetes or metabolic syndrome.

No Insurance, No Clinic Visits, No Hassle

MEDVi is a cash-pay telehealth service. There are no insurance pre-authorizations, no copays, no clinic waiting rooms, and no pharmacy lines. Everything, from intake to prescription to delivery, happens online, and your monthly MEDVi rate covers the medication, the clinician, the shipping, and the ongoing support.

Locked Refill Pricing on Semaglutide

MEDVi advertises a flat $299 per month refill rate on compounded semaglutide injections that does not increase as your dose escalates. For patients titrating up to maintenance doses, this is a meaningful cost advantage over providers that charge by dose level.

Both Injection and Tablet Delivery Formats

MEDVi offers both weekly injections and daily oral tablets for semaglutide and tirzepatide. This dual-format approach gives patients flexibility based on lifestyle, needle preference, and individual tolerability.

MEDVi Pricing Plans and Treatment Options

Compounded Semaglutide Injections

From $179 First Month

The most accessible entry point into MEDVi. Includes the medication, physician evaluation, personalized treatment plan, free shipping, and ongoing telehealth support. Refills are priced at $299 per month at a locked rate that does not increase with dose escalation.

Compounded Semaglutide Tablets

From $249 First Month

The needle-free alternative for patients who prefer daily oral dosing. Includes the same clinical evaluation, treatment plan, and ongoing support as the injection program.

Compounded Tirzepatide Injections

From $349 First Month

The dual-action MEDVi program. Tirzepatide targets both GLP-1 and GIP receptors, which clinical research on branded tirzepatide suggests may produce greater average weight loss than semaglutide alone. Refill pricing varies by dose.

MEDVi Satisfaction and Refund Policy

MEDVi advertises a money-back guarantee on its weight loss program — if you follow the program for the required treatment window without achieving meaningful weight loss results, you may qualify for a refund (typically minus a percentage allocated to consultation fees). The specific terms, eligibility criteria, and refund window are detailed in the MEDVi terms of service.

Because MEDVi involves prescription medications, refund policies differ from typical supplement guarantees. Before enrolling, read the full MEDVi guarantee language and cancellation procedure on the official site, note your billing cycle dates, and keep records of all clinical and customer service correspondence. The MEDVi support team is available to walk you through plan adjustments, dose changes, treatment pauses, or cancellations. Always verify the current MEDVi refund and cancellation terms directly on the official MEDVi site before placing your first order.

Frequently Asked Questions About MEDVi

Is MEDVi safe?

MEDVi connects patients with licensed, board-certified providers who make independent prescribing decisions. The GLP-1 active ingredients prescribed through MEDVi are backed by extensive clinical research in their FDA-approved branded forms. However, compounded versions are not individually FDA-approved as finished products. Always disclose your complete medical history during your MEDVi intake.

Is MEDVi legitimate?

Yes, MEDVi is a legitimate telehealth platform. It is LegitScript certified, partners with licensed U.S. compounding pharmacies, and connects patients with board-certified providers through the OpenLoop Health clinician network. As with any healthcare service, customer experiences vary.

How quickly does MEDVi work?

Most MEDVi patients report appetite reduction within the first 1 to 3 weeks of treatment. Initial weight changes typically appear at 4 to 8 weeks. More significant results, 10 percent or more of body weight, usually develop over 3 to 6 months of consistent treatment combined with diet and lifestyle support. Individual results vary.

Does MEDVi accept insurance?

No. MEDVi is a strictly cash-pay telehealth service. There are no insurance approvals, copays, or coverage limits, you pay one transparent monthly rate that includes medication, consultation, shipping, and support. HSA and FSA cards may be accepted at checkout.

What are the side effects of MEDVi medications?

The most commonly reported side effects of GLP-1 medications include nausea, constipation, diarrhea, fatigue, and mild gastrointestinal discomfort, especially during dose escalation. The MEDVi titration protocol is designed to minimize these effects by starting low and increasing gradually under provider supervision. Discuss any side effects with your prescribing MEDVi clinician.

Are MEDVi medications FDA-approved?

MEDVi primarily prescribes compounded versions of semaglutide and tirzepatide, which are prepared by licensed U.S. compounding pharmacies. Compounded medications use the same active ingredients as FDA-approved drugs (Wegovy, Ozempic, Mounjaro, Zepbound), but the finished compounded products themselves are not individually evaluated by the FDA for safety, efficacy, or quality. MEDVi also offers brand-name Wegovy and Ozempic for patients who prefer FDA-approved options.

Where can I buy MEDVi?

MEDVi is available exclusively through the official MEDVi website. Buying through the official site ensures genuine medications, licensed clinician oversight, LegitScript-certified service, and access to the MEDVi money-back guarantee.

Is MEDVi a supplement?

No. MEDVi is not a dietary supplement. It is a telehealth platform that connects patients with licensed clinicians who prescribe prescription GLP-1 medications prepared by compounding pharmacies or dispensed as brand-name products.

Buy MEDVi Today and Take Control of Your Weight Loss Journey

Stop overpaying for the same compounded medications. MEDVi combines the science of GLP-1 therapy, the safety of board-certified clinician oversight, LegitScript-certified service, and transparent monthly pricing into one accessible weight loss program. Start your confidential MEDVi health assessment today on the official site and find out if you qualify.

I switched to MEDVi after paying almost double at another telehealth provider for what turned out to be the same compounded medication. The pricing is locked, the meds arrive cold and on time, and the support team responds to messages within hours. No upsells, no pressure to escalate my dose. I am sticking with MEDVi.

James M.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
U.S. Food and Drug Administration. Drug Approval Package: Wegovy (semaglutide).
U.S. Food and Drug Administration. Drug Approval Package: Zepbound (tirzepatide).
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity.

FDA Disclaimer and Important Safety Information

These statements have not been evaluated by the Food and Drug Administration. The information presented on this page is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.

MEDVi is a telehealth platform that connects patients with independent, licensed healthcare providers through the OpenLoop Health clinician network. MEDVi is not a pharmacy and does not manufacture, dispense, or sell medications directly. MEDVi does not employ the prescribing clinicians and does not influence clinical determinations — all prescribing decisions rest with the treating provider based on the medical information provided during the patient intake.

About Compounded Medications: MEDVi primarily prescribes compounded versions of semaglutide and tirzepatide, which are prepared by licensed U.S. compounding pharmacies operating in FDA-regulated facilities. Compounded medications use FDA-approved active pharmaceutical ingredients, but the finished compounded products are not individually reviewed or approved by the FDA for safety, efficacy, or quality. The FDA generally advises that compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug or during recognized shortages. Potency, purity, and stability may vary between compounded formulations, and compounded GLP-1 products are not interchangeable with FDA-approved versions. Availability of compounded GLP-1 medications may change depending on FDA shortage determinations and applicable state laws.

Prescription Medication Notice: The GLP-1 medications prescribed through MEDVi (including semaglutide and tirzepatide) are prescription-only drugs. They should be used only under the supervision of a licensed healthcare provider. Do not start, stop, or change your dose without consulting your prescribing clinician.

Potential Side Effects: Common side effects of GLP-1 receptor agonist medications may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, and injection site reactions. Serious side effects — though rare — may include pancreatitis, gallbladder problems, kidney issues, and severe allergic reactions. GLP-1 medications carry a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Not Suitable For Everyone: MEDVi medications are not appropriate for pregnant or breastfeeding women, individuals under 18 years of age, or patients with certain medical conditions. Always disclose your complete medical history, current medications, and known allergies during your online assessment.

Brand Name Trademarks: Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective owners (Novo Nordisk and Eli Lilly). MEDVi is not affiliated with, endorsed by, or sponsored by these trademark holders. References to these brand names are for educational and comparative purposes only.

Individual Results Vary: Weight loss results vary based on adherence, dose, individual metabolism, diet, physical activity, and other lifestyle factors. Patient testimonials presented reflect individual experiences and are not a guarantee of results. Self-reported MEDVi patient outcomes do not represent a randomized clinical trial.

Money-Back Guarantee Terms: MEDVi’s money-back guarantee is subject to specific eligibility criteria, including program adherence requirements and a refund window. Refund amounts may exclude consultation fees. Always review the full guarantee language on the official MEDVi site before enrolling.

Consult Your Healthcare Provider: The content on this page is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.

By using MEDVi, you acknowledge that you have read, understood, and agreed to the full Terms of Service, Privacy Policy, and Telehealth Consent available on the official MEDVi website.